China Biologic Products (CBPO) Tops Q4 EPS by 11c

China Biologic Products (NASDAQ: CBPO) reported Q4 EPS of $0.95, $0.11 better than the analyst estimate of $0.84. Revenue for the quarter came in at $77.6 million versus the consensus estimate of $76.22 million.

For earnings history and earnings-related data on China Biologic Products (CBPO) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c
• Inhibrx, Inc. (INBX) Misses Q2 EPS by 54c